达托霉素在婴儿中的应用：两例有药物峰浓度和谷浓度的病例报告。
Daptomycin use in infants: report of two cases with peak and trough drug concentrations.
作者信息
Cohen-Wolkowiez M, Smith P B, Benjamin D K, Fowler V G, Wade K C
机构信息
Department of Pediatrics, Duke University, Durham, NC, USA.
出版信息
J Perinatol. 2008 Mar;28(3):233-4. doi: 10.1038/sj.jp.7211898.
Abstract
We report two infants treated with daptomycin for methicillin-resistant Staphylococcus aureus infection and describe peak and trough blood concentrations measured during therapy. The peak concentrations were 41.7 and 36.7 mcg ml(-1), and the 12-hour trough concentrations were 12.7 and 16.3 mcg ml(-1), respectively. Even though the infants received higher doses than adults, their drug concentrations were comparable to those observed in adults treated with regular dosing of daptomycin.
摘要
我们报告了两名接受达托霉素治疗耐甲氧西林金黄色葡萄球菌感染的婴儿，并描述了治疗期间测得的血药峰浓度和谷浓度。峰浓度分别为41.7和36.7 mcg/ml，12小时谷浓度分别为12.7和16.3 mcg/ml。尽管婴儿接受的剂量高于成人，但其药物浓度与接受常规剂量达托霉素治疗的成人中观察到的浓度相当。
相似文献
1
Daptomycin use in infants: report of two cases with peak and trough drug concentrations.
J Perinatol. 2008 Mar;28(3):233-4. doi: 10.1038/sj.jp.7211898.
2
Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin.
Ann Pharmacother. 2010 May;44(5):918-21. doi: 10.1345/aph.1M665. Epub 2010 Mar 30.
3
Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
J Clin Microbiol. 2006 Feb;44(2):595-7. doi: 10.1128/JCM.44.2.595-597.2006.
4
Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin.
J Clin Microbiol. 2005 Oct;43(10):5384-7. doi: 10.1128/JCM.43.10.5384-5387.2005.
5
Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.
Clin Infect Dis. 2005 Apr 1;40(7):1058-60. doi: 10.1086/428616. Epub 2005 Feb 17.
6
Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia.
Clin Infect Dis. 2013 Dec;57(11):1568-76. doi: 10.1093/cid/cit582. Epub 2013 Sep 17.
7
Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
J Clin Microbiol. 2008 Mar;46(3):1132-6. doi: 10.1128/JCM.01844-07. Epub 2008 Jan 16.
8
Daptomycin Dose Optimization in Pediatric Staphylococcus aureus Bacteremia: A Pharmacokinetic/Pharmacodynamic Investigation.
J Clin Pharmacol. 2024 Jul;64(7):860-865. doi: 10.1002/jcph.2425. Epub 2024 Mar 18.
9
Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis.
Antimicrob Agents Chemother. 2013 Feb;57(2):864-72. doi: 10.1128/AAC.02000-12. Epub 2012 Dec 3.
10
Daptomycin for eradication of a systemic infection with a methicillin-resistant-Staphylococcus aureus in a biventricular assist device recipient.
Ann Thorac Surg. 2007 Jul;84(1):269-70. doi: 10.1016/j.athoracsur.2007.02.001.
引用本文的文献
1
Ceftaroline and Daptomycin Combination Antibiotic Therapy for a Methicillin-Resistant Liver Abscess in a Premature Infant.
J Pediatr Pharmacol Ther. 2022;27(8):754-759. doi: 10.5863/1551-6776-27.8.754. Epub 2022 Nov 17.
2
High alanine aminotransaminase associated with daptomycin use in a premature infant.
J Mother Child. 2021 Oct 11;25(1):65-68. doi: 10.34763/jmotherandchild.20212501.d-20-00020.
3
Daptomycin Pharmacokinetics in Adolescents Undergoing Hemodialysis and Peritoneal Dialysis: A Case Series With Pharmacokinetic Modeling.
J Pediatr Pharmacol Ther. 2021;26(2):123-132. doi: 10.5863/1551-6776-26.2.123. Epub 2021 Feb 15.
4
Safety and Efficacy of Daptomycin in Neonates with Coagulase-Negative Staphylococci: Case Series Analysis.
Antibiotics (Basel). 2021 Feb 7;10(2):168. doi: 10.3390/antibiotics10020168.
5
The Use of Daptomycin in the Treatment of Persistent Coagulase-Negative Staphylococcal Sepsis in Premature Infants: A Case Series.
J Pediatr Pharmacol Ther. 2021;26(1):92-98. doi: 10.5863/1551-6776-26.1.92. Epub 2021 Jan 4.
6
Clinical Pharmacokinetics of Daptomycin.
Clin Pharmacokinet. 2021 Mar;60(3):271-281. doi: 10.1007/s40262-020-00968-x. Epub 2020 Dec 14.
7
Methicillin-Resistant Staphylococcus aureus Endovascular Infection in a Neonate: Prolonged, Safe, and Effective Use of Daptomycin and Enoxaparin.
J Pediatr Pharmacol Ther. 2020 Jan-Feb;25(1):68-74. doi: 10.5863/1551-6776-25.1.68.
8
The Use of Daptomycin to Treat Methicillin-Resistant Staphylococcus Epidermidis Bacteremia in a Critically Ill Child with Renal Failure.
J Pediatr Pharmacol Ther. 2017 Jul-Aug;22(4):300-303. doi: 10.5863/1551-6776-22.4.300.
9
Dosing antibiotics in neonates: review of the pharmacokinetic data.
Future Microbiol. 2017 Sep;12(11):1001-1016. doi: 10.2217/fmb-2017-0058. Epub 2017 Jul 31.
10
Successful Use of Daptomycin in a Preterm Neonate With Persistent Methicillin-Resistant Staphylococcus epidermidis Bacteremia.
J Pediatr Pharmacol Ther. 2015 Jan-Feb;20(1):61-5. doi: 10.5863/1551-6776-20.1.61.
本文引用的文献
1
Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.
Antimicrob Agents Chemother. 2003 Apr;47(4):1318-23. doi: 10.1128/AAC.47.4.1318-1323.2003.
Zotero 插件